eLife (Dec 2022)

Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors

  • Minsu Kang,
  • Hee Young Na,
  • Soomin Ahn,
  • Ji-Won Kim,
  • Sejoon Lee,
  • Soyeon Ahn,
  • Ju Hyun Lee,
  • Jeonghwan Youk,
  • Haesook T Kim,
  • Kui-Jin Kim,
  • Koung Jin Suh,
  • Jun Suh Lee,
  • Se Hyun Kim,
  • Jin Won Kim,
  • Yu Jung Kim,
  • Keun-Wook Lee,
  • Yoo-Seok Yoon,
  • Jee Hyun Kim,
  • Jin-Haeng Chung,
  • Ho-Seong Han,
  • Jong Seok Lee

DOI
https://doi.org/10.7554/eLife.78636
Journal volume & issue
Vol. 11

Abstract

Read online

We aimed to elucidate the evolutionary trajectories of gallbladder adenocarcinoma (GBAC) using multi-regional and longitudinal tumor samples. Using whole-exome sequencing data, we constructed phylogenetic trees in each patient and analyzed mutational signatures. A total of 11 patients including 2 rapid autopsy cases were enrolled. The most frequently altered gene in primary tumors was ERBB2 and TP53 (54.5%), followed by FBXW7 (27.3%). Most mutations in frequently altered genes in primary tumors were detectable in concurrent precancerous lesions (biliary intraepithelial neoplasia [BilIN]), but a substantial proportion was subclonal. Subclonal diversity was common in BilIN (n=4). However, among subclones in BilIN, a certain subclone commonly shrank in concurrent primary tumors. In addition, selected subclones underwent linear and branching evolution, maintaining subclonal diversity. Combined analysis with metastatic tumors (n=11) identified branching evolution in nine patients (81.8%). Of these, eight patients (88.9%) had a total of 11 subclones expanded at least sevenfold during metastasis. These subclones harbored putative metastasis-driving mutations in cancer-related genes such as SMAD4, ROBO1, and DICER1. In mutational signature analysis, six mutational signatures were identified: 1, 3, 7, 13, 22, and 24 (cosine similarity >0.9). Signatures 1 (age) and 13 (APOBEC) decreased during metastasis while signatures 22 (aristolochic acid) and 24 (aflatoxin) were relatively highlighted. Subclonal diversity arose early in precancerous lesions and clonal selection was a common event during malignant transformation in GBAC. However, selected cancer clones continued to evolve and thus maintained subclonal diversity in metastatic tumors.

Keywords